Ginkgo biloba: indications, mechanisms, and safety
Abstract
Ginkgo biloba special extract (EGb761) is used in most randomized control trials. Indications include cognition and memory in Alzheimer disease, age-associated dementia, cerebral insufficiency, intermittent claudication, schizophrenia, and multi-infarct dementia. Dosages range from 80 to 720 mg/d for durations of 2 weeks to 2 years. Mechanisms of action include increasing cerebral blood flow, antioxidant and antiinflammatory effects, with antiplatelet effects attributed to flavone and terpene lactones. Possible interactions with monoamine oxidase inhibitors, alprazolam, haloperidol, warfarin, and nifedipine have been reported. Optimal dosage/duration, dose-response characteristics, drug interactions, bioavailability, long-term effects, and optimal intervention timing should be the focus of future work.
Referenced for these plants
How to cite
Diamond, B.J. and Bailey, M.R (2013) 'Ginkgo biloba: indications, mechanisms, and safety', Psychiatric Clinics of North America, 36(1), pp. 73-83. doi:10.1016/j.psc.2012.12.006
This reference is part of the evidence base for the Omnia Sana plant database. Source links open the original publication; Omnia Sana does not host third-party content.